ViPOR treatment for relapsed or hard-to-treat lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This Phase 1/2 trial tests a combination of several medicines (venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid) for lymphoma that has come back or did not respond. It aims to shrink tumors safely and improve responses in people with specific types of B-cell lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed B-cell lymphoma by lab pathology or lab tests
- Your lymphoma type is one of these: DLBCL (and related), follicular lymphoma, or mantle cell lymphoma (CLL/SLL is not allowed)
- Your lymphoma must have come back or not responded after at least one prior treatment (as specified for your lymphoma type)
- You must have signs of measurable or evaluable lymphoma on exam, scans, and/or lab testing
- You must be age 18 or older, and able to do study visits (performance status 0–2)
- Your blood and organ tests must be high enough for safe treatment (or the issues must be from the lymphoma)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
This trial tests a combination of targeted drugs (capivasertib and venetoclax) with a gentle form of chemotherapy for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) that has come back or has not responded to previous treatment. The goal is to see if this approach is safe and effective.
This trial tests a combination of two drugs, rituximab and venetoclax, as a first treatment for marginal zone lymphoma that has not been treated before. The goal is to see if this drug pair is safe and effective.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.